ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease

By: Newsfile

Dallas, Texas--(Newsfile Corp. - June 1, 2023) - Stonegate Healthcare Partners (SHP), a healthcare strategy consulting firm, is pleased to announce the release of a thematic report that examines innovative advancements in the treatment of diabetic eye disease, including diabetic retinopathy (DR) and diabetic macular edema (DME). The report, Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease, highlights the unmet needs and the companies leading innovation in this field. Companies highlighted in the report include Oculis (NASDAQ: OCS) Ocuphire Pharma, OcuTerra, Rezolute (NASDAQ: RZLT) Roche (ROG.SW) and Unity Biotechnology. This thematic report will serve as the foundation for Stonegate Healthcare's ongoing market intelligence in diabetic eye disease, providing valuable insights for investors and companies.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • The future of diabetic eye disease treatment lies in beyond VEGF therapies.
  • Based on interviews and analysis with dozens of companies and KOLs, this report offers an important resource for anyone seeking an understanding of diabetic eye disease treatment.
  • The therapies highlighted in the report include VEGF-agnostic mechanisms of action, systemic control of disease, non-invasive administration, and potentially preventative treatments.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7294/168375_figure1_550.jpg

Click image above to view full announcement.


About Stonegate Healthcare
The Stonegate Healthcare mission is to accelerate meaningful innovations in healthcare through Strategy, Market Intelligence, Business Development and Investor Outreach. The firm's research approach revolves around conducting comprehensive comparative analyses in specific medical fields in order to identify assets and technologies with the highest disruptive potential. Stonegate Healthcare builds on its foundational thematic research by continuously gathering market intelligence, enabling a current understanding of emerging disruptive technologies.

For further information or to obtain a copy of the full report, please contact alamgir@stonegateinc.comĀ 

Contacts:

Shiv Kapoor
Shiv@stonegateinc.com

Stonegate Healthcare Partners
(214) 987-4121
alamgir@stonegateinc.com

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/168375

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.